TROGARZO

(Ibalizumab)

PreclinicalMonoclonal antibody

TTheratechnologies

TROGARZO is one of 55 small molecule programs targeting HIV infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

HIV InfectionActive, not recruiting

HIV InfectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

123 competitors in HIV Infection

#DrugCompanyPhaseTrials

Zofran

Viread

Zometa

Agenerase

GGlaxo Dba Glaxosmithkline

Approved

4 5

Calciferol

Crestor

Istodax

Marinol

Neoral

Tybost

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Drug1 trial

Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

Completed·TTaiMed Biologics Inc.·Phase 3·NCT02475629·40 enrolled

Treatment1 trial

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

Completed·TTaiMed Biologics Inc.·Phase 3·NCT02707861·79 enrolled

Monoclonal1 trial

Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1

Completed·TTaiMed Biologics Inc.·Phase 2·NCT00784147·113 enrolled

HIV infection1 trial

Compassionate Use of Ibalizumab for the Treatment of HIV Infection

No longer available·UUniversity of Colorado, Denver··NCT02028819

Trial1 trial

External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA

Completed·EEpividian··NCT05495204·141 enrolled

Regulatory

FDA Approval Timeline[4]

Mar 6, 2018

TROGARZO

BLA BLA761065

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Ibalizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ibalizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ibalizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761065). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Theratechnologies company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Preclinical[1]
Company: TTheratechnologies

TROGARZO

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Drug1 trial

Treatment1 trial

Monoclonal1 trial

HIV infection1 trial

Trial1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News